Effect of combination of molnupiravir with clarithromycin on blood biomarkers in patients with mild-to-moderate COVID-19
Background: Molnupiravir is a type of medication used to treat coronavirus disease 2019 (COVID-19). However, no evidence regarding the therapeutic effect of molnupiravir combined with clarithromycin (CAM) on blood biomarkers is available.
Methods: Of the 156 rehabilitation patients, 124 patients with mild-to-moderate COVID-19 were treated with molnupiravir. Among these 124 patients, 54 were treated with CAM. The remaining 28 rehabilitation patients were negative for COVID-19. Blood biomarkers were assessed after administration of molnupiravir in patients receiving molnupiravir plus CAM or molnupiravir alone.
Results: Among the measured blood biomarkers, lactate dehydrogenase, potassium, white blood cells, C-reacted protein, neutron–lymphocyte ratio, fibrin degradation product, and prothrombin time–international normalized ratio values were significantly higher (P < 0.05) in the molnupiravir alone group than in the molnupiravir plus CAM group, and lymphocytes were significantly lower (P < 0.05) on day 5 after admission. In the molnupiravir plus CAM group, immunoglobulin (Ig) A levels increased and soluble interleukin 2-receptor levels (sIL2R) decreased (P < 0.05) on day 14 after admission. In addition, COVID-19-negative patients had higher IgA levels and lower sIL2R levels compared to infected patients (P < 0.05). The concomitant administration of molnupiravir plus CAM resulted in fewer sequelae after 12 months, and the incidence of venous thromboembolism was significantly reduced (P < 0.05).
Conclusion: In patients with mild-to-moderate COVID-19, concomitant administration of molnupiravir plus CAM showed several non-worsening blood biomarkers, elevated immune activity, and reduced post-infection sequelae.
Relevance for Patients: After administration of molnupiravir to patients with mild-to-moderate COVID-19, administration of CAM to patients suffering from secondary macrolide-sensitive bacterial infection was compared with administration of molnupiravir alone. D-dimer, IgA, and sIL2R are potential predictive factors of disease severity in critically ill patients with COVID-19.
[1] Kamal L, Ramadan A, Farraj S, Bahig L, Ezzat S. The Pill of Recovery; Molnupiravir for Treatment of COVID-19 Patients; a Systematic Review. Saudi Pharm J 2022;30:508-18. doi: 10.1016/j.jsps.2022.03.002
[2] Singh AK, Singh A, Singh R, Misra A. An Updated Practical Guideline on Use of Molnupiravir and Comparison with Agents having Emergency Use Authorization for Treatment of COVID-19. Diabetes Metab Syndr 2022;16:102396. doi: 10.1016/j.dsx.2022.102396
[3] WHO Updates its Treatment Guidelines to Include Molnupiravir. News Release Geneva; 2022. Available from: https://www.who.int/news/item/03-03-2022- molnupiravir [Last accessed on 2022 Mar 03].
[4] Liu Y, Ge L, Fan S, Xu A, Wang X, Dong X, et al. Disease Progression of Hospitalized Elderly Patients with Omicron BA.2 Treated with Molnupiravir. Infect Dis Ther 2022;11:2241-51. doi: 10.1007/s40121-022-00716-7
[5] Batiha GE, Zayed MA, Awad AA, Shaheen HM, Mustapha S, Herrera-Calderon O, et al. Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19. Front Med (Lausanne) 2021;8:642313.
[6] Rashad A, Nafady A, Hassan MH, Mansour H, Taya U, Bazeed SE, et al. Therapeutic Efficacy of Macrolides in Management of Patients with Mild COVID-19. Sci Rep 2021;11:16361. doi: 10.1038/s41598-021-95900-z
[7] Millán-Oñate J, Millan W, Mendoza LA, Sánchez CG, Fernandez-Suarez H, Bonilla-Aldana DK, et al. Successful Recovery of COVID-19 Pneumonia in a Patient from Colombia After Receiving Chloroquine and Clarithromycin. Ann Clin Microbiol Antimicrob 2020;19:16. doi: 10.1186/s12941-020-00358-y
[8] Snow TA, Longobardo A, Brealey D, Down J, Satta G, Singer M, et al. Beneficial Ex Vivo Immunomodulatory and Clinical Effects of Clarithromycin in COVID-19. J Infect Chemother 2022;28:948-54. doi: 10.1016/j.jiac.2022.04.001
[9] Takahashi E, Kataoka K, Indalao IL, Konoha K, Fujii K, Chida J, et al. Oral Clarithromycin Enhances Airway Immunoglobulin A (IgA) Immunity through Induction of IgA Class Switching Recombination and B-cellActivating Factor of the Tumor Necrosis Factor Family Molecule on Mucosal Dendritic Cells in Mice Infected with Influenza A Virus. J Virol 2012;86:10924-34. doi: 10.1128/JVI.01207-12
[10] Sugiyama K, Shirai R, Mukae H, Ishimoto H, Nagata T, Sakamoto N, et al. Differing Effects of Clarithromycin and Azithromycin on Cytokine Production by Murine Dendritic Cells. Clin Exp Immunol 2007;147:540-6.
[11] Tsiakos K, Tsakiris A, Tsibris G, Voutsinas PM, Panagopoulos P, Kosmidou M, et al. Early Start of Oral Clarithromycin is Associated with Better Outcome in COVID-19 of Moderate Severity: The ACHIEVE OpenLabel Single-Arm Trial. Infect Dis Ther 2021;10:2333-51. doi: 10.1007/s40121-021-00505-8
[12] Guidelines for Pathogen Testing of Novel Coronavirus Infectious Disease (COVID-19) March 17, 2022, Version 5.1 published by the Ministry of Health, Labor and Welfare of Japan. Available from: https://www.mhlw.go.jp/ content/000914399.pdf [Last accessed on 2022 Dec 22].
[13] Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate Dehydrogenase Levels Predict Coronavirus Disease 2019 (COVID-19) Severity and Mortality: A Pooled Analysis. Am J Emerg Med 2020;38:1722-6. doi: 10.1016/j.ajem.2020.05.073
[14] Zinellu A, Paliogiannis P, Fois AG, Solidoro P, Carru C, Mangoni AA. Cholesterol and Triglyceride Concentrations, COVID-19 Severity, and Mortality: A Systematic Review and Meta-Analysis with Meta-Regression. Front Public Health 2021;9:705916. doi: 10.3389/fpubh.2021.705916
[15] Li G, Wu X, Zhou CL, Wang YM, Song B, Cheng XB, et al. Uric Acid as a Prognostic Factor and Critical Marker of COVID-19. Sci Rep 2021;11:17791. doi: 10.1038/s41598-021-96983-4
[16] Sacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Gaspari P, Stecca A, et al. SARS-CoV-2 Infection as a Trigger of Autoimmune Response. Clin Transl Sci 2021;14:898-907. doi: 10.1111/cts.12953
[17] Noori M, Nejadghaderi SA, Sullman MJ, CarsonChahhoud K, Kolahi AA, Safiri S. Epidemiology, Prognosis and Management of Potassium Disorders in Covid-19. Rev Med Virol 2022;32:e2262. doi: 10.1002/rmv.2262
[18] Palladino M. Complete Blood Count Alterations in COVID-19 Patients: A Narrative Review. Biochem Med (Zagreb) 2021;31:030501. doi: 10.11613/BM.2021.030501
[19] Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, et al. Prognostic Value of C-Reactive Protein in Patients with Coronavirus 2019. Clin Infect Dis 2020;71:2174-9. doi: 10.1093/cid/ciaa641
[20] Keski H. Hematological and Inflammatory Parameters to Predict the Prognosis in COVID-19. Indian J Hematol Blood Transfus 2021;37:534-42. doi: 10.1007/s12288-021-01407-y
[21] Sarkar PG, Pant P, Kumar J, Kumar A. Does Neutrophilto-lymphocyte Ratio at Admission Predict Severity and Mortality in COVID-19 Patients? A Systematic Review and Meta-analysis. Indian J Crit Care Med 2022;26:361-75. doi: 10.5005/jp-journals-10071-24135
[22] Wool GD, Miller JL. The Impact of COVID-19 Disease on Platelets and Coagulation. Pathobiology 2021;88:15-27. doi: 10.1159/000512007
[23] Ouyang SM, Zhu HQ, Xie YN, Zou ZS, Zuo HM, Rao YW, et al. Temporal Changes in Laboratory Markers of Survivors and Non-survivors of Adult Inpatients with COVID-19. BMC Infect Dis 2020;20:952. doi: 10.1186/s12879-020-05678-0
[24] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. Lancet 2020;395:1054-62. doi: 10.1016/S0140-6736(20)30566-3
[25] Dhamoon MS, Thaler A, Gururangan K, Kohli A, Sisniega D, Wheelwright D, et al. Acute Cerebrovascular Events with COVID-19 Infection. Stroke 2021;52:48-56. doi: 10.1161/STROKEAHA.120.031668
[26] Islam B, Ahmed M, Islam Z, Begum SM. Severe Acute Myopathy Following SARS-CoV-2 Infection: A Case Report and Review of Recent Literature. Skelet Muscle 2021;11:10. doi: 10.1186/s13395-021-00266-5
[27] Rey JR, Caro-Codón J, Rosillo SO, Iniesta AM, Castrejón-Castrejón S, Marco-Clement I, et al. Heart Failure in COVID-19 Patients: Prevalence, Incidence and Prognostic Implications. Eur J Heart Fail 2020;22: 2205-15. doi: 10.1002/ejhf.1990
[28] Peghin M, De Martino M, Fabris M, Palese A, Visintini E, Graziano E, et al. The Fall in Antibody Response to SARS-CoV-2: A Longitudinal Study of Asymptomatic to Critically Ill Patients up to 10 Months After Recovery. J Clin Microbiol 2021;59:e0113821. doi: 10.1128/JCM.01138-21
[29] Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, et al. IgA Dominates the Early Neutralizing Antibody Response to SARS-CoV-2. Sci Transl Med 2021;13:eabd2223. doi: 10.1126/scitranslmed.abd2223
[30] Jing X, Xu M, Song D, Yue T, Wang Y, Zhang P, et al. Association Between Inflammatory Cytokines and antiSARS-CoV-2 Antibodies in Hospitalized Patients with COVID-19. Immun Ageing 2022;19:12. doi: 10.1186/s12979-022-00271-2
[31] Gooding R, Riches P, Dadian G, Moore J, Gore M. Increased Soluble Interleukin-2 Receptor Concentration in Plasma Predicts a Decreased Cellular Response to IL-2. Br J Cancer 1995;72:452-5. doi: 10.1038/bjc.1995.354
[32] Ozaki A, Sawano T, Saito H, Tanimoto T, Tsubokura M. Will Initial Consultation Patterns among Undiagnosed Cancer Patients be the Same After this COVID-19 Pandemic? Experiences from the 2011 Triple Disaster in Fukushima, Japan. J Glob Health 2020;10:020343. doi: 10.7189/jogh.10.020343
[33] Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Viant C, Gaebler C, et al. Enhanced SARS-CoV-2 Neutralization by Dimeric IgA. Sci Transl Med 2021;13:eabf1555. doi: 10.1126/scitranslmed.abf1555
[34] Santani BG, LeBlanc BW, Thakare RP. Molnupiravir for the Treatment of COVID-19. Drugs Today (Barc) 2022;58:335-50. doi: 10.1358/dot.2022.58.7.3419558
[35] Painter GR, Natchus MG, Cohen O, Holman W, PainterWP. Developing a Direct Acting, Orally Available Antiviral Agent in a Pandemic: The Evolution of Molnupiravir as a Potential Treatment for COVID-19. Curr Opin Virol 2021;50:17-22. doi: 10.1016/j.coviro.2021.06.003
[36] Gonda K, Kanazawa H, Maeda G, Matayoshi C, Hirose N, Katsumoto Y, et al. Ingestion of Okinawa Island Vegetables Increases IgA Levels and Prevents the Spread of Influenza RNA Viruses. Nutrients 2021;13:1773. doi: 10.3390/nu13061773
[37] Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Reyes VD, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med 2022;386:509-20. doi: 10.1056/NEJMoa2116044
[38] Poddighe D, Aljofan M. Clinical Evidences on the Antiviral Properties of Macrolide Antibiotics in the COVID-19 Era and Beyond. Antivir Chem Chemother 2020;28:2040206620961712. doi: 10.1177/2040206620961712
[39] Kumar D, Trivedi N. Disease-drug and Drug-Drug Interaction in COVID-19: Risk and Assessment. Biomed Pharmacother 2021;139:111642. doi: 10.1016/j.biopha.2021.111642